Form 4: Director John W. Kozarich Receives LGND Equity Grant
Statement of Changes in Beneficial Ownership
Ligand Pharmaceuticals Director John W. Kozarich was granted 836 restricted stock units and 2,938 stock options following the company's annual meeting.
Summary
- Director John W. Kozarich acquired 836 restricted stock units (RSUs) on June 5, 2026.
- Director John W. Kozarich was granted 2,938 non-qualified stock options with an exercise price of $237.00.
- The grants were issued as part of the annual meeting of the Board of Directors.
- Both the RSUs and the stock options are scheduled to vest on the earlier of the next annual meeting or the first anniversary of the grant date.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.
Positives
- Alignment of director interests with shareholders through equity-based compensation.
- Standardized vesting schedule ensures long-term commitment from board members.
Negatives
- Issuance of equity grants results in minor dilution to existing shareholders.
Risks
- Potential for future share price volatility affecting the value of the granted options.
- Market performance risks associated with the pharmaceutical sector.
Future Outlook
The equity grants vest on the earlier of the next annual meeting or the first anniversary of the grant date, indicating a standard one-year retention cycle for board members.
Industry Context
StockSavvy.ai notes that annual equity grants to non-employee directors are standard corporate governance practice in the biotechnology and pharmaceutical industries to ensure board alignment with long-term shareholder value.
Comparison to Industry Standards
- The use of RSUs and stock options for director compensation is consistent with peer companies in the mid-cap pharmaceutical sector.
- Vesting schedules of one year are standard practice for annual director equity awards.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Compensation | Annual equity grant to Director John W. Kozarich. | 06/05/2026 | Standard alignment of director incentives with company performance. |
Stakeholder Impact
- Minor dilution for existing shareholders due to the issuance of new equity.
Next Steps
- Vesting of the granted RSUs and options on or before June 5, 2027.
Key Dates
| Date | Description |
|---|---|
| 06/05/2026 | Date of the annual meeting and grant of equity securities. |
| 06/09/2026 | Date of filing the Form 4 with the SEC. |
| 06/05/2036 | Expiration date of the granted stock options. |
Keywords
Ligand Pharmaceuticals, LGND, Form 4, Insider Trading, Equity Grant, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.